{"classes":[{"categories":[{"measurements":[{"comment":"The median and upper limit of 95% CI could not be calculated as they were not reached.","groupId":"OG000","lowerLimit":"27.4","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"6.7","upperLimit":"24.5","value":"18.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"DoR was defined as the time from date for first documented response of CR or PR until the first documented response of progression per RECIST 1.1 or death in the absence of progression. DoR was calculated using the Kaplan-Meier technique.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in the durvalumab (MEDI4736) monotherapy group were to receive durvalumab 10 mg/kg Q2W via intravenous infusion for up to 12 months.","id":"OG000","title":"Durvalumab (MEDI4736)"},{"description":"Patients in the placebo group were to receive matching placebo for intravenous infusion Q2W for up to 12 months.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized patients, analyzed on an ITT basis. Only patients with an objective response were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~ 12 weeks thereafter until confirmed disease progression. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.","title":"Duration of Response (DoR) Based on BICR Assessments According to RECIST 1.1","type":"SECONDARY","unitOfMeasure":"Months"}